285 related articles for article (PubMed ID: 27938358)
1. High strength extrafine pMDI beclometasone/formoterol (200/6 μg) is effective in asthma patients not adequately controlled on medium-high dose of inhaled corticosteroids.
Paggiaro P; Corradi M; Latorre M; Raptis H; Muraro A; Gessner C; Siergiejko Z; Scuri M; Petruzzelli S
BMC Pulm Med; 2016 Dec; 16(1):180. PubMed ID: 27938358
[TBL] [Abstract][Full Text] [Related]
2. Extrafine beclomethasone/formoterol combination via a dry powder inhaler (NEXThaler(®)) or pMDI and beclomethasone monotherapy for maintenance of asthma control in adult patients: A randomised, double-blind trial.
Kanniess F; Scuri M; Vezzoli S; Francisco C; Petruzzelli S
Pulm Pharmacol Ther; 2015 Feb; 30():121-7. PubMed ID: 25088067
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the effect of beclometasone/formoterol in asthma patients after methacholine-induced bronchoconstriction: A noninferiority study using metered dose vs. dry powder inhaler.
Singh D; van den Berg F; Leaker B; Corradi M; Jabbal S; Collarini S; Mongelli V; Santoro L; Piccinno A; Biondaro S; Lipworth B
Br J Clin Pharmacol; 2019 Apr; 85(4):729-736. PubMed ID: 30586199
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of an extrafine fixed pMDI combination of beclometasone dipropionate/formoterol fumarate in adolescent asthma.
Kuna P; Govoni M; Lucci G; Scuri M; Acerbi D; Stelmach I
Br J Clin Pharmacol; 2015 Sep; 80(3):569-80. PubMed ID: 25808292
[TBL] [Abstract][Full Text] [Related]
5. The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study).
Singh D; Schröder-Babo W; Cohuet G; Muraro A; Bonnet-Gonod F; Petruzzelli S; Hoffmann M; Siergiejko Z;
Respir Med; 2016 May; 114():84-90. PubMed ID: 27109816
[TBL] [Abstract][Full Text] [Related]
6. Acute cardiovascular safety of two formulations of beclometasone dipropionate/formoterol fumarate in COPD patients: A single-dose, randomised, placebo-controlled crossover study.
Singh D; Ciurlia G; Piccinno A; Muraro A; Bocchi M; Scuri M
Pulm Pharmacol Ther; 2017 Feb; 42():43-51. PubMed ID: 28065679
[TBL] [Abstract][Full Text] [Related]
7. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials.
Virchow JC; Kuna P; Paggiaro P; Papi A; Singh D; Corre S; Zuccaro F; Vele A; Kots M; Georges G; Petruzzelli S; Canonica GW
Lancet; 2019 Nov; 394(10210):1737-1749. PubMed ID: 31582314
[TBL] [Abstract][Full Text] [Related]
8. Comparison of extrafine beclomethasone dipropionate/formoterol fumarate dry powder inhaler and pressurized metered-dose inhaler in Chinese patients with asthma: the FORTUNE study.
Zheng J; Zhang J; Fu X; Lin C; Zhang X; Mei X; Corradi M; Cappellini G; Calabro E; Zhu C; Topole E
J Asthma; 2024 Apr; 61(4):360-367. PubMed ID: 37878325
[TBL] [Abstract][Full Text] [Related]
9. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over.
Shepherd J; Rogers G; Anderson R; Main C; Thompson-Coon J; Hartwell D; Liu Z; Loveman E; Green C; Pitt M; Stein K; Harris P; Frampton GK; Smith M; Takeda A; Price A; Welch K; Somerville M
Health Technol Assess; 2008 May; 12(19):iii-iv, 1-360. PubMed ID: 18485271
[TBL] [Abstract][Full Text] [Related]
10. Bronchodilating effects of a new beclometasone dipropionate plus formoterol fumarate formulation via pressurized metered-dose inhaler in asthmatic children: a double-blind, randomized, cross-over clinical study.
Pohunek P; Varoli G; Reznichenko Y; Mokia-Serbina S; Brzostek J; Kostromina V; Kaladze M; Muraro A; Carzana E; Armani S; Kaczmarek J
Eur J Pediatr; 2021 May; 180(5):1467-1475. PubMed ID: 33404895
[TBL] [Abstract][Full Text] [Related]
11. Treatment response according to small airways disease status: The effects of high-strength extrafine pMDI beclomethasone dipropionate/formoterol fumarate in fixed dose combination in moderate uncontrolled asthmatic patients.
Carpagnano GE; Scioscia G; Lacedonia D; Stornelli SR; Irene Quarato CM; Soccio P; Resta O; Foschino Barbaro MP
Pulm Pharmacol Ther; 2020 Feb; 60():101879. PubMed ID: 31866498
[TBL] [Abstract][Full Text] [Related]
12. Inhaled beclometasone dipropionate/formoterol fumarate extrafine fixed combination for the treatment of asthma.
Crisafulli E; Zanini A; Pisi G; Pignatti P; Poli G; Scuri M; Chetta A
Expert Rev Respir Med; 2016; 10(5):481-90. PubMed ID: 26938578
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial.
Zheng J; Baldi S; Zhao L; Li H; Lee KH; Singh D; Papi A; Grapin F; Guasconi A; Georges G
Respir Res; 2021 Mar; 22(1):90. PubMed ID: 33757520
[TBL] [Abstract][Full Text] [Related]
14. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
Singh D; Papi A; Corradi M; Pavlišová I; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Vestbo J
Lancet; 2016 Sep; 388(10048):963-73. PubMed ID: 27598678
[TBL] [Abstract][Full Text] [Related]
15. Stepping-across controlled asthmatic patients to extrafine beclometasone/formoterol combination.
Barnes N; van Noord JA; Brindicci C; Lindemann L; Varoli G; Perpiña M; Guastalla D; Casula D; Patel S; Chanez P;
Pulm Pharmacol Ther; 2013 Oct; 26(5):555-61. PubMed ID: 23524015
[TBL] [Abstract][Full Text] [Related]
16. High-dose beclometasone dipropionate/formoterol fumarate in fixed-dose combination for the treatment of asthma.
Corradi M; Spinola M; Petruzzelli S; Kuna P
Ther Adv Respir Dis; 2016 Oct; 10(5):492-502. PubMed ID: 27340255
[TBL] [Abstract][Full Text] [Related]
17. Beclometasone dipropionate/formoterol: in an HFA-propelled pressurised metered-dose inhaler.
Dhillon S; Keating GM
Drugs; 2006; 66(11):1475-83; discussion 1484-5. PubMed ID: 16906779
[TBL] [Abstract][Full Text] [Related]
18. Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER.
Singh D; Virchow JC; Canonica GW; Vele A; Kots M; Georges G; Papi A
Respir Res; 2020 Oct; 21(1):285. PubMed ID: 33121501
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of budesonide/formoterol pMDI vs budesonide pMDI in asthmatic children (6-<12 years).
Pearlman DS; Eckerwall G; McLaren J; Lamarca R; Puu M; Gilbert I; Jorup C; Sandin K; Lanz MJ
Ann Allergy Asthma Immunol; 2017 Apr; 118(4):489-499.e1. PubMed ID: 28256307
[TBL] [Abstract][Full Text] [Related]
20. Real-life effectiveness of extrafine beclometasone dipropionate/formoterol in adults with persistent asthma according to smoking status.
Brusselle G; Peché R; Van den Brande P; Verhulst A; Hollanders W; Bruhwyler J
Respir Med; 2012 Jun; 106(6):811-9. PubMed ID: 22357130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
